Integral Health Asset Management’s Alto Neuroscience ANRO Stock Holding History

Integral Health Asset Management’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	500,000 +125,000	+33%	+$2.32M	0.54%	49
2025 Q4	$6.67M	Sell	375,000 -25,000	-6%	-$315K	0.33%	64
2025 Q3	$1.61M	Hold	400,000	–	–	0.11%	74
2025 Q2	$880K	Hold	400,000	–	–	0.08%	72
2025 Q1	$864K	Buy	400,000 +100,000	+33%	+$358K	0.09%	79
2024 Q4	$1.27M	Buy	+300,000	New	+$1.87M	0.11%	80

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Integral Health Asset Management's ANRO Position: Q1 2026 in Review

Integral Health Asset Management increased its Alto Neuroscience (ANRO) stake by 33% in Q1 2026, buying an estimated $2.32M and bringing the position to 500,000 shares worth $11.2M. The position accounts for 0.54% of the portfolio, ranked #49.

Integral Health Asset Management first reported a position in ANRO in Q4 2024 and has held it in 6 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

Integral Health Asset Management held 500,000 shares of Alto Neuroscience worth $11.2M as of Q1 2026.
Integral Health Asset Management bought 125,000 Alto Neuroscience shares in Q1 2026, an estimated $2.32M.
Alto Neuroscience made up 0.54% of Integral Health Asset Management's portfolio in Q1 2026, its #49 holding.
Integral Health Asset Management first reported a position in Alto Neuroscience in Q4 2024 and has held it in 6 quarters since.
110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.